Table 1. Patient baseline clinical characteristics and univariate Cox regression analysis for prediction of mortality at 6 and 24 months after CRT-implantation.

		mortality at 6 months				mortality at 24 months
	Total cohort	HR	95% CI	χ2	p	HR	95% CI	χ2	p
Age (years)	67 (60–72)	1.25	0.58–2.66	0.34	0.55	1.07	0.69–1.67	0.10	0.74
Male	72 (78%)	2.23	0.44–11.75	0.96	0.33	1.62	0.45–5.83	0.55	0.46
Ischaemic ethiology	46 (49%)	1.29	0.34–4.82	0.15	0.69	1.97	0.82–4.71	2.35	0.12
NYHA III/IV	81 (87%)	1.19	0.15–9.57	0.02	0.86	3.22	0.43–23.99	1.30	0.25
LBBB	84 (90%)	0.45	0.09–2.18	0.96	0.32	0.42	0.15–1.16	2.78	0.09
QRS-duration (ms)	160 (150–180)	0.41	0.19–0.91	4.77	0.02	0.59	0.36–0.97	4.30	0.03
CRT-D	43 (46%)	1.47	0.39–5.48	0.33	0.56	1.27	0.55–2.95	0.32	0.56
Optimal lead position	68 (73%)	1.21	0.25–5.82	0.05	0.81	1.37	0.50–3.75	0.37	0.54
Diabetes mellitus	29 (31%)	1.09	0.27–4.39	0.01	0.89	1.92	0.83–4.64	2.35	0.12
Hypertension	48 (51%)	0.45	0.11–1.81	1.24	0.26	0.62	0.26–1.46	1.16	0.28
Atrial fibrillation	26 (27%)	1.25	0.31–5.00	0.10	0.75	1.28	0.51–3.18	0.29	0.58
BB	85 (91%)	0.15	0.03–0.62	6.89	0.009	0.49	0.14–1.67	1.27	0.25
ACEi/ARB	88 (94%)	0.24	0.05–1.19	3.01	0.08	0.56	0.13–2.44	0.58	0.44
Diuretics	76 (81%)	1.79	0.22–14.31	0.30	0.58	2.15	0.50–9.28	1.07	0.30
AA	69 (74%)	0.25	0.06–0.93	4.21	0.04	1.03	0.38–2.81	0.00	0.94

Hazard ratios refer to 1 standard deviation increase in case of continuous variables and presence versus absence in case of categorical variables. HR: hazard ratio, CI: confidence interval, χ²: wald chi square, NYHA: New York Heart Association Classification, LBBB: left bundle branch block, CRT-D: cardiac resynchronisation therapy with defibrillator, BB: beta-blocker, ACEi/ARB: angiotensin convertase inhibitor/angiotensin receptor blocker, AA: aldosterone antagonist, LVEF: left ventricular ejection fraction, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, MI: mitral insufficiency.